Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

NCT04643327 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease
Mild Cognitive Impairment
Memory Impairment

Interventions

DRUG: Levetiracetam
DRUG: Placebo

Sponsor

The University of Queensland

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]